Titre : Paralysie pseudobulbaire

Paralysie pseudobulbaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement C3
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Paralysie pseudobulbaire : Questions médicales les plus fréquentes", "headline": "Paralysie pseudobulbaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Paralysie pseudobulbaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-02", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Paralysie pseudobulbaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Paralysie", "url": "https://questionsmedicales.fr/mesh/D010243", "about": { "@type": "MedicalCondition", "name": "Paralysie", "code": { "@type": "MedicalCode", "code": "D010243", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.888.592.636" } } }, "about": { "@type": "MedicalCondition", "name": "Paralysie pseudobulbaire", "alternateName": "Pseudobulbar Palsy", "code": { "@type": "MedicalCode", "code": "D020828", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Kenjiro Kunieda", "url": "https://questionsmedicales.fr/author/Kenjiro%20Kunieda", "affiliation": { "@type": "Organization", "name": "Neurology, Gifu University Graduate School of Medicine, Gifu, JPN." } }, { "@type": "Person", "name": "Tomohisa Ohno", "url": "https://questionsmedicales.fr/author/Tomohisa%20Ohno", "affiliation": { "@type": "Organization", "name": "Dentistry, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN." } }, { "@type": "Person", "name": "Ichiro Fujishima", "url": "https://questionsmedicales.fr/author/Ichiro%20Fujishima", "affiliation": { "@type": "Organization", "name": "Rehabilitation Medicine, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN." } }, { "@type": "Person", "name": "Victor Kekere", "url": "https://questionsmedicales.fr/author/Victor%20Kekere", "affiliation": { "@type": "Organization", "name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA." } }, { "@type": "Person", "name": "Patrice Fouron", "url": "https://questionsmedicales.fr/author/Patrice%20Fouron", "affiliation": { "@type": "Organization", "name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Plasma complement C3 and C3a are increased in major depressive disorder independent of childhood trauma.", "datePublished": "2022-11-29", "url": "https://questionsmedicales.fr/article/36447174", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12888-022-04410-3" } }, { "@type": "ScholarlyArticle", "name": "Complement gene mutations in children with C3 glomerulopathy: do they affect the response to mycophenolate mofetil?", "datePublished": "2023-12-02", "url": "https://questionsmedicales.fr/article/38041748", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00467-023-06231-2" } }, { "@type": "ScholarlyArticle", "name": "Changes in serum TIM-3 and complement C3 expression in workers due to Mn exposure.", "datePublished": "2023-11-09", "url": "https://questionsmedicales.fr/article/38026392", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2023.1289838" } }, { "@type": "ScholarlyArticle", "name": "Complement C3 as a potential drug target in periodontitis: Evidence from the cis-Mendelian randomization approach.", "datePublished": "2023-11-05", "url": "https://questionsmedicales.fr/article/37926509", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jcpe.13894" } }, { "@type": "ScholarlyArticle", "name": "Microglia refine developing retinal astrocytic and vascular networks through the complement C3/C3aR axis.", "datePublished": "2023-03-01", "url": "https://questionsmedicales.fr/article/36762625", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1242/dev.201047" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Signes et symptômes", "item": "https://questionsmedicales.fr/mesh/D012816" }, { "@type": "ListItem", "position": 4, "name": "Manifestations neurologiques", "item": "https://questionsmedicales.fr/mesh/D009461" }, { "@type": "ListItem", "position": 5, "name": "Paralysie", "item": "https://questionsmedicales.fr/mesh/D010243" }, { "@type": "ListItem", "position": 6, "name": "Paralysie pseudobulbaire", "item": "https://questionsmedicales.fr/mesh/D020828" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Paralysie pseudobulbaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Paralysie pseudobulbaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Paralysie pseudobulbaire", "description": "Comment diagnostique-t-on la paralysie pseudobulbaire ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes aident au diagnostic ?\nLa paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?\nPeut-on confondre cette paralysie avec d'autres troubles ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+C3&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Paralysie pseudobulbaire", "description": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?\nLa difficulté à parler est-elle un symptôme courant ?\nLes patients ressentent-ils de la douleur ?\nY a-t-il des variations dans les symptômes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+C3&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Paralysie pseudobulbaire", "description": "Peut-on prévenir la paralysie pseudobulbaire ?\nComment réduire le risque de paralysie pseudobulbaire ?\nLes AVC peuvent-ils être prévenus ?\nLa réhabilitation précoce aide-t-elle à prévenir la paralysie ?\nLes habitudes alimentaires influencent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+C3&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Paralysie pseudobulbaire", "description": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?\nLa rééducation est-elle utile ?\nLes médicaments peuvent-ils réduire les symptômes ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils efficaces pour tous les patients ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+C3&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Paralysie pseudobulbaire", "description": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?\nLa dépression est-elle une complication fréquente ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques d'isolement social ?\nLes complications peuvent-elles être traitées ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+C3&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Paralysie pseudobulbaire", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de paralysie pseudobulbaire ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie peut-il influencer le risque ?\nLes maladies cardiovasculaires sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+C3&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la paralysie pseudobulbaire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes neurologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie cérébrale comme l'IRM peuvent être utilisés pour identifier les lésions." } }, { "@type": "Question", "name": "Quels symptômes aident au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des accès de rire ou de pleurs inappropriés et des troubles de la parole." } }, { "@type": "Question", "name": "La paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent associée à des maladies neurologiques comme la sclérose en plaques ou les AVC." } }, { "@type": "Question", "name": "Peut-on confondre cette paralysie avec d'autres troubles ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec d'autres troubles affectant le contrôle émotionnel et moteur." } }, { "@type": "Question", "name": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux symptômes incluent des crises de rire ou de pleurs incontrôlables." } }, { "@type": "Question", "name": "La difficulté à parler est-elle un symptôme courant ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent éprouver des difficultés à articuler et à contrôler leur voix." } }, { "@type": "Question", "name": "Les patients ressentent-ils de la douleur ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La paralysie pseudobulbaire ne cause généralement pas de douleur physique, mais des malaises émotionnels." } }, { "@type": "Question", "name": "Y a-t-il des variations dans les symptômes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en intensité et en fréquence d'un patient à l'autre." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement, les symptômes peuvent s'aggraver et affecter la qualité de vie." } }, { "@type": "Question", "name": "Peut-on prévenir la paralysie pseudobulbaire ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais la gestion des maladies sous-jacentes peut aider." } }, { "@type": "Question", "name": "Comment réduire le risque de paralysie pseudobulbaire ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain et traiter les affections neurologiques peut réduire le risque." } }, { "@type": "Question", "name": "Les AVC peuvent-ils être prévenus ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en contrôlant les facteurs de risque comme l'hypertension et le diabète, on peut réduire les AVC." } }, { "@type": "Question", "name": "La réhabilitation précoce aide-t-elle à prévenir la paralysie ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une réhabilitation précoce après un AVC ou une lésion cérébrale peut aider à prévenir la paralysie." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles le risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut contribuer à la santé neurologique et réduire les risques." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments comme les antidépresseurs et la thérapie comportementale." } }, { "@type": "Question", "name": "La rééducation est-elle utile ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rééducation orthophonique peut aider à améliorer les capacités de communication." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils réduire les symptômes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent réduire la fréquence et l'intensité des épisodes émotionnels." } }, { "@type": "Question", "name": "Y a-t-il des traitements non médicamenteux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la thérapie psychologique peuvent également être bénéfiques." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous les patients ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements peut varier selon les individus et la gravité des symptômes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles de la déglutition et des problèmes de communication." } }, { "@type": "Question", "name": "La dépression est-elle une complication fréquente ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent développer une dépression en raison de l'impact émotionnel de la maladie." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des risques d'isolement social ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les difficultés de communication peuvent entraîner un isolement social pour les patients." } }, { "@type": "Question", "name": "Les complications peuvent-elles être traitées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées avec des traitements appropriés et un soutien." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les AVC, les maladies neurodégénératives et les traumatismes crâniens sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de paralysie pseudobulbaire ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente avec l'âge, surtout chez les personnes âgées ayant des antécédents médicaux." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies neurologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le mode de vie peut-il influencer le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les maladies cardiovasculaires sont-elles un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies cardiovasculaires augmentent le risque de paralysie pseudobulbaire par AVC." } } ] } ] }

Sources (1986 au total)

Plasma complement C3 and C3a are increased in major depressive disorder independent of childhood trauma.

Dysregulated complement system is linked to pathophysiology of major depressive disorder (MDD). Childhood trauma has been associated with an increased incidence of adult depression via a putative mech... The participants were 49 medication-free MDD patients and 45 healthy controls. All participants were asked to finish the Childhood Trauma Questionnaire, followed by blood sampling for measurement of p... Peripheral plasma concentration of C3 and C3a in medication-free MDD group was significantly higher than that in the healthy controls; whereas the concentration of plasma C1q and CRP in depressed pati... Our data suggest that complement C3 and C3a may be implicated in the pathophysiology of MDD, although traumatic childhood experiences were not associated with the circulating levels of complement C3, ...

Complement gene mutations in children with C3 glomerulopathy: do they affect the response to mycophenolate mofetil?

C3 glomerulopathy (C3G) is a complement-mediated disease. Although genetic studies are not required for diagnosis, they are valuable for treatment planning and prognosis prediction. The aim of this st... Sixty pediatric C3G patients were included, divided into two groups based on complement-related gene mutations. Demographic and clinical-pathological findings, treatment modalities, and outcome data w... Out of the 60 patients, 17 had mutations. The most common mutation was in the CFH gene (47%). The mean age at diagnosis was higher in the group with mutation (12.9 ± 3.6 vs. 11.2 ± 4.1 years, p = 0.03... This study is the largest pediatric C3G study examining the relationship between genotype and phenotype. We showed that the mutation group often presented with asymptomatic urinary abnormalities, was ...

Complement C3 as a potential drug target in periodontitis: Evidence from the cis-Mendelian randomization approach.

Evidence from a Phase IIa trial showed that a complement C3-targeted drug reduced gingival inflammation in patients with gingivitis. Using drug-target Mendelian randomization (MR), we investigated whe... We used multiple 'cis' instruments from the vicinity of the encoding loci of C3. Instrument selection was restricted to the drug target encoding loci (chromosome 19; 6,677,715-6,730,573 (GRCh37/hg19))... MR analysis revealed that the inhibition of C3 reduces the odds of periodontitis (OR 0.91 per 1 standard deviation reduction in C3; 95% confidence interval 0.87-0.96, p value = .0003).... Findings from our MR analysis suggest a potential protective effect of C3 blockade against periodontitis....

Serum C3 complement levels predict prognosis and monitor disease activity in Guillain-Barré syndrome.

Biomarkers are needed to predict prognosis and disease activity in patients with Guillain-Barré syndrome (GBS). The complement system is a key player in the pathogenesis of GBS. This study aimed to as... We reviewed the medical records of 76 GBS patients with C3 and C4 measurements during hospitalization between 2010 and 2021. Clinical outcomes were correlated with baseline serum C3, C4, and seven add... Higher C3, but not C4, was associated with poorer outcomes: lower Medical Research Council sum scores (MRCSS), higher GBS disability score (GBSDS), longer hospitalization, and more frequent treatment-... This study highlights the use of serum C3 as a novel mechanistic biomarker in GBS. Larger prospective studies are needed to validate our findings....

Relationship Between Serum Complement C3 Levels and Outcomes Among Patients With Anti-GBM Disease.

IgG and complement 3 (C3) are generally found to be deposited along the glomerular basement membrane (GBM) in human anti-GBM disease. The pathogenic role of complement activation in kidney damage of a... Ninety-four anti-GBM disease patients between January 2004 and December 2020 at the National Clinical Research Center of Kidney Diseases Jinling Hospital were retrospectively analyzed, and were divide... A total of 94 patients (aged 43.6 ± 16.2; male patients, 46%) with anti-GBM disease were enrolled. There were 26 patients with low C3 levels and 68 patients with normal C3 levels. Compared with the no... The kidney outcomes of anti-GBM disease in the low C3 group were poorer than those in the normal C3 group. The influence of C3 on the kidney outcomes of patients with anti-GBM disease may be of clinic...

Comparative analysis of complement C3 and C4 serum levels for outcome prediction in ANCA-associated renal vasculitis.

The activation of the complement system contributes essentially to the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis. We here aimed to directly compare levels... Serum levels of complement components C3 and C4 were directly compared in association with clinical and outcome data in a retrospective cohort of ANCA-associated renal vasculitis.... As compared to poor outcome prediction by low levels of complement C3 (p = 0.0093), low levels of complement C4 did not associate with early requirement of kidney replacement therapy (KRT) or death (p... While low levels of complement C3 were superior in predicting poor outcome in ANCA-associated renal vasculitis, a minor fraction with poor outcome had isolated C4 lowering not captured by serum C3 mea...

Implication of platelets and complement C3 as link between innate immunity and tubulointerstitial injury in renal vasculitis with MPO-ANCA seropositivity.

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a potentially life-threatening systemic small-vessel vasculitis that is characterized by pauci-immune glomerulonephritis, depi... A cohort of 53 biopsy-proven cases of ANCA-associated renal vasculitis were retrospectively enrolled in a single-center observational study. Univariate and multivariate regression analysis was perform... Lower platelet counts correlated with markers of kidney injury including eGFR loss (... Based on our observation that an association between platelets and complement system activation is only observed in the MPO-ANCA subgroup, this could implicate that platelets and complement C3 link in...